Invention Grant
- Patent Title: PIK3CA fusions
-
Application No.: US16287438Application Date: 2019-02-27
-
Publication No.: US10669590B2Publication Date: 2020-06-02
- Inventor: Ethan G. Cerami , Christoph Lengauer , Nicolas Stransky
- Applicant: BLUEPRINT MEDICINES CORPORATION
- Applicant Address: US MA Cambridge
- Assignee: Blueprint Medicines Corporation
- Current Assignee: Blueprint Medicines Corporation
- Current Assignee Address: US MA Cambridge
- Agency: Finnegan, Henderson, Farabow, Garrett and Dunner, LLP
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; C07H21/04 ; C12Q1/6886 ; A61K31/7088 ; C12N15/113 ; C12Q1/6806 ; C12Q1/6813
Abstract:
The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) gene fusions, and fragments of those gene fusions. The invention further provides methods of diagnosing and treating diseases or disorders associated with PIK3CA fusions, such as conditions mediated by PIK3CA aberrant expression or activity, or overexpression of PIK3CA.
Public/Granted literature
- US20190185942A1 PIK3CA FUSIONS Public/Granted day:2019-06-20
Information query
